The Potential Rise in the Price of Corbus Pharmaceuticals Holdings Inc (CRBP) following insiders activity

Corbus Pharmaceuticals Holdings Inc’s filing revealed that its Director Jenkins John Kenneth unloaded Company’s shares for reported $20465.0 on May 30 ’25. In the deal valued at $7.35 per share,2,783 shares were sold. As a result of this transaction, Jenkins John Kenneth now holds 33 shares worth roughly $236.28.

Then, Altmeyer Anne sold 1,392 shares, generating $10,096 in total proceeds. Upon selling the shares at $7.25, the Director now owns 1,391 shares.

Before that, Smethurst Dominic sold 6,393 shares. Corbus Pharmaceuticals Holdings Inc shares valued at $43,330 were divested by the Chief Medical Officer at a price of $6.78 per share. As a result of the transaction, Smethurst Dominic now holds 70,807 shares, worth roughly $0.51 million.

William Blair initiated its Corbus Pharmaceuticals Holdings Inc [CRBP] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. Wedbush began covering CRBP with “an Outperform” recommendation on July 30, 2024.

Price Performance Review of CRBP

On Tuesday, Corbus Pharmaceuticals Holdings Inc [NASDAQ:CRBP] saw its stock jump 3.77% to $7.16. Over the last five days, the stock has lost -10.05%. Corbus Pharmaceuticals Holdings Inc shares have fallen nearly -83.68% since the year began. Nevertheless, the stocks have fallen -39.32% over the past one year. While a 52-week high of $61.90 was reached on 01/16/25, a 52-week low of $4.64 was recorded on 04/07/25.

Levels Of Support And Resistance For CRBP Stock

The 24-hour chart illustrates a support level at 6.86, which if violated will result in even more drops to 6.56. On the upside, there is a resistance level at 7.32. A further resistance level may holdings at 7.48.

How much short interest is there in Corbus Pharmaceuticals Holdings Inc?

A steep rise in short interest was recorded in Corbus Pharmaceuticals Holdings Inc stocks on 2025-06-13, dropping by 17285.0 shares to a total of 1.87 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 1.89 million shares. There was a decline of -0.92%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on June 26, 2024 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $85 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.